Systematic photodynamic therapy for concurrent cervical-vaginal high-grade squamous intraepithelial lesion: a series...

Concurrent cervical-vaginal high-grade squamous intraepithelial lesion (HSIL) is increasingly prevalent with carcinogenic potential. For gynecologic oncologists, non-invasive, organ-preserving treatment of this condition remains a challenge. While Hiporfin-photodynamic therapy (PDT) has proven effective for cervical HSIL or vaginal HSIL alone, its efficacy in concurrent cervical-vaginal HSIL remains unreported. We treated 8 pathologically confirmed patients with Hiporfin-PDT: 2.0 mg/kg intravenous Hiporfin followed by 630-nm red laser irradiation 48-72 h later, with one session per patient initially. At 3-6 months, the complete response (CR) rate was 75.0% (6/8); the 2 partial response (PR) patients achieved CR after a second PDT session or two sessions of thermocoagulation. Our preliminary findings suggest that Hiporfin-PDT has potential feasibility as a non-invasive option for concurrent cervical-vaginal HSIL, warranting further investigation.